Refractory focal segmental glomerulosclerosis in the adult: Complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab

BMJ Case Reports

Volumn , Issue , 2014, Pages

  Marasà, Maddalena ^a   Cravedi, Paolo ^b   Ruggiero, Barbara ^a   Ruggenenti, Piero ^a,c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AZATHIOPRINE; CD19 ANTIGEN; PREDNISONE; RITUXIMAB;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CASE REPORT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CLEARANCE; LYMPHOCYTE DEPLETION; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REMISSION; SINGLE DRUG DOSE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907300011     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2014-205507     Document Type: Article

References (37)

1. Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004;44:815.
2. D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med 2011;365:2398-411.
3. Hogan J, Mohan P, Appel GB. Diagnostic tests and treatment options in glomerular disease: 2014 update. Am J Kidney Dis 2014;63:656-66.
4. Van Husen M, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2011;26:881-92.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guidelines for glomerulonephritis. Kidney Int Suppl 2012;2:139-274.
6. Ravani P, Ponticelli A, Siciliano C, et al. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 2013;84:1025-33.
7. Ruggenenti P, Ruggiero B, Cravedi P, et al. Rituximab in steroid-dependent or frequently-relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 2014;25:850-63.
8. Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol 2013;9:154-69.
9. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006;354:1961-3. (Pubitemid 43872718)
10. Marasà M, Kopp JB. Monoclonal antibodies for podocytopathies: rationale and clinical responses. Nat Rev Nephrol 2009;5:337-48.
11. Gulati A, Sinha A, Jordan SC, et al. Efficacy and safety of treatment with rituximab for dif ficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010;5:2207-12.
12. Ito S, Kamei K, Ogura M, et al. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol 2013;28:257-64.
13. Fernandez-Fresnedo G, Segarra A, González E, et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009;4:1317-23.
14. Peters HP, van de Kar NC, Wetzels JF. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature. Neth J Med 2008;66:408-15.
15. Kisner T, Burst V, Teschner S, et al. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature. Nephron Clin Pract 2012;120:c79-85.
16. Ruggenenti P, Cravedi P, Remuzzi G. Rituximab for membranous nephropathy and immune disease: less might be enough. Nat Clin Pract Nephrol 2009;5:76-7.
17. Cravedi P, Ruggenenti P, Sghirlanzoni MC, et al. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007;2:932-7.
18. Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 1985;106:522-6. (Pubitemid 15140671)
19. Frassinetti Castelo Branco Camurça Fernandes P, Bezerra Da Silva G Jr, De Sousa Barros FA, et al. Treatment of steroid-resistant nephrotic syndrome with cyclosporine: study of 17 cases and a literature review. J Nephrol 2005;18:711-20. (Pubitemid 43090674)
20. Hamasaki Y, Yoshikawa N, Nakazato H, et al . Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol 2013;28:765-71.
21. Yokoyama H, Shimizu M, Wada T, et al. The beneficial effects of lymphocytapheresis for treatment of nephrotic syndrome. Ther Apher 2002;6:167-73. (Pubitemid 34507310)
22. Russo GE, Cavallini M, Centi A, et al. Extracorporeal photochemotherapy for the treatment of glomerulopathies with associated nephrotic syndrome. J Nephrol 2010;23:85-9.
23. Yokoyama H, Wada T, Zhang W, et al. Advances in apheresis therapy for glomerular diseases. Clin Exp Nephrol. 2007;11:122-7. (Pubitemid 47012509)
24. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996;7:56-63. (Pubitemid 26068448)
25. Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43:1377-84. (Pubitemid 23161428)
26. Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999;56:2220-6. (Pubitemid 30004751)
27. Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011;80:868-78.
28. Nakayama M, Kamei K, Nozu K, et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 2008;23:481-5.
29. Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996;334:878-83. (Pubitemid 26107345)
30. Hertig A, Droz D, Lesavre P, et al. SLE and idiopathic nephrotic syndrome: coincidence or not? Am J Kidney Dis 2002;40:1179-84. (Pubitemid 35403129)
31. Dantal J, Godfrin Y, Koll R, et al. Antihuman immunoglobulin affinity immunoadsorbtion strongly decreases proteinuria in patients with relapsing nephroticsyndrome. J Am Soc Nephrol 1998;9:1709-15. (Pubitemid 28405079)
32. Kessel A, Rosner I, Toubi E. Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol 2008;34:74-9.
33. Cravedi P, Sghirlanzoni MC, Marasà M, et al. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol 2011;33:461-8.
34. Filler G, Huang SH, Sharma AP. Should we consider MMF therapy after rituximab for nephrotic syndrome? Pediatr Nephrol 2011;26:1759-62.
35. Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011;3:85ra46.
36. Chan AC. Rituximab's new therapeutic target: the podocyte actin cytoskeleton. Sci Transl Med 2011;3:85ps21.
37. Apolone G, Mosconi P, Ware JE Jr. Questionario sullo stato di salute SF-36, A. Milano: Guerrini e Associati, 1997.